Efficacy and safety of BRAF/MEK inhibitors in BRAFV600E-mutated anaplastic thyroid cancer: a systematic review and meta-analysis
ConclusionsOur study demonstrated BRAFi/MEKi have a decent activity for BRAFV600E ATC patients, especially in the neoadjuvant setting, with a tolerable safety profile. However, further clinical trials are warranted to investigate these findings.
Source: Endocrine - Category: Endocrinology Source Type: research
More News: Cancer | Cancer & Oncology | Clinical Trials | Databases & Libraries | Endocrinology | Neoadjuvant Therapy | Study | Thyroid | Thyroid Cancer